This protocol applies to patients with mild cytomegalovirus (CMV) esophagitis — a presentation where the severity of disease is compatible with an oral treatment strategy.
In mild CMV esophagitis, management centers on an oral antiviral regimen. The full protocol defines the specific agent, dose, and course — the complete algorithm is available via the link below.
The clinical goal is resolution of signs and symptoms of CMV esophagitis within 21–42 days.
Valganciclovir 900 mg PO every 12 hours can be used in patients with mild disease (AIII).
Oral valganciclovir can be used in patients with mild disease (AIII).
21–42 days or until signs and symptoms have resolved (AIII).
View source ↗